Circulating oxidised low-density lipoprotein functions as a potent driver of endothelial dysfunction, systemic inflammation, and unstable vascular plaque architecture. Recently, a secondary analysis of the landmark INSPIRES randomised trial evaluated this pivotal biomarker in acute cerebrovascular events. The study examined whether elevated baseline concentrations could predict clinical deterioration. Consequently, researchers discovered that oxidised low-density lipoprotein independently portends both recurrent ischaemic events and significant haemorrhagic complications within 90 days. These compelling findings highlight an urgent need to re-evaluate residual atherogenic risk in acute secondary stroke prevention.

Atherosclerotic Biology of Oxidised Low-Density Lipoprotein

Lipid peroxidation fundamentally alters circulating low-density lipoprotein particles, generating immunogenic neo-epitopes that trigger severe inflammatory cascades. Specifically, oxidised low-density lipoprotein stimulates scavenger receptors on arterial macrophages, accelerating foam cell creation and fatty streak maturation. Furthermore, this modified particle promotes vascular smooth muscle migration and triggers continuous endothelial apoptosis. As a result, the vulnerable fibrous cap thins significantly, rendering atherosclerotic plaques prone to abrupt rupture and arterial thrombosis.

In cerebral vessels, this destructive biological sequence creates substantial instability. Moreover, elevated circulating concentrations degrade the microvascular endothelial barrier by unleashing matrix metalloproteinases and reactive oxygen species. Consequently, heightened vascular fragility accompanies active arterial thrombosis, creating a complex bi-directional threat. Traditional lipid panels primarily quantify static circulating cholesterol pools without reflecting underlying oxidative modifications. Therefore, standard low-density lipoprotein cholesterol metrics frequently overlook this critical biological burden. In contrast, circulating oxidised low-density lipoprotein reflects ongoing oxidative and enzymatic distress directly within vascular tissues. Ultimately, assessing this modified lipid provides unique pathophysiological insight into unstable cerebrovascular plaque behaviour.

Key Clinical Insights from the INSPIRES Trial Cohort

The multicentre INSPIRES trial enrolled patients presenting with acute mild ischaemic stroke or high-risk transient ischaemic attack harboring intracranial or extracranial atherosclerosis. In this comprehensive secondary analysis, investigators evaluated 5,814 qualified participants to determine how baseline biomarker concentrations shaped 90-day recovery trajectories. Specifically, a blinded core laboratory measured baseline circulating concentrations with precise immunoassays. Overall, the cohort displayed an average age of 63.7 years, and women comprised 36.0% of participants.

Across the entire cohort, the mean baseline concentration of circulating oxidised low-density lipoprotein reached 36.62 µg/dL. Subsequently, researchers divided patients into distinct tertiles to evaluate clinical outcomes through multivariable Cox proportional hazards regression models. After rigorous adjustment for traditional vascular risk factors, patients in the highest tertile faced an elevated hazard of any stroke within 90 days compared with the lowest tertile (hazard ratio 1.39). Similarly, these individuals experienced a noticeable increase in composite vascular events (hazard ratio 1.36). While ischaemic stroke trends also pointed toward elevated risk (hazard ratio 1.31), the broad hazard spanned across diverse vascular territories. Thus, the prospective data firmly establish high baseline concentrations as an objective indicator of early vascular recurrence.

The Dual Threat of Recurrent Ischaemia and Haemorrhage

Perhaps the most striking outcome from this secondary investigation involves safety endpoints. Notably, individuals residing in the highest tertile exhibited a marked 3.6-fold surge in moderate-to-severe haemorrhagic events (hazard ratio 3.61, 95% confidence interval 1.26 to 10.34). Clinicians conventionally associate lipid fractions solely with occlusive atherothrombotic complications. However, this robust association demonstrates that intensive oxidative stress undermines microvascular structural competence.

Furthermore, patients with acute cerebrovascular disease often receive intensive dual antiplatelet therapy alongside high-potency statins. When severe vascular oxidative stress coexists with potent platelet inhibition, microvascular rupture becomes far more probable. In particular, oxidised low-density lipoprotein stimulates local inflammatory cytokines that dissolve tight junction proteins between brain capillary endothelial cells. Consequently, cerebral microvessels lose mechanical integrity, predisposing patients to microbleeds and haemorrhagic transformation of ischaemic tissue. In addition, peripheral systemic bleeding can accelerate under severe systemic endothelial destabilization. Therefore, clinicians must appreciate that oxidative lipid stress does not merely accelerate thrombosis. Instead, it simultaneously heightens bleeding susceptibility during aggressive secondary antithrombotic management, presenting a delicate therapeutic dilemma.

Clinical Implications for Acute Secondary Prevention

These findings carry direct practical significance for clinical neurologists, internists, and emergency physicians managing acute stroke. Currently, guideline-directed management mandates aggressive early antiplatelet protocols and intensive statin therapy for patients with documented atherosclerotic disease. However, significant residual risk persists among many individuals despite reaching target low-density lipoprotein cholesterol thresholds. Therefore, incorporating markers of oxidative stress could bridge the diagnostic gap between standard lipid panels and real-time clinical vulnerability.

Moreover, identifying patients with pronounced oxidative stress could help clinicians tailor therapeutic intensity. For example, clinicians could exercise heightened vigilance for intracranial microbleeds or gastrointestinal haemorrhage when selecting dual antiplatelet regimens. Additionally, persistent elevation of oxidised low-density lipoprotein might signal the necessity for earlier add-on lipid-modifying agents, such as ezetimibe or PCSK9 inhibitors. These adjunct therapies reduce overall atherogenic particle count and temper systemic inflammatory drives. Furthermore, lifestyle interventions that mitigate systemic oxidative stress, including smoking cessation and strict glycaemic control, become paramount. Thus, evaluating oxidative lipid biology can refine individualised risk stratification during the fragile ninety-day post-stroke window.

Future Directions in Cerebrovascular Biomarker Research

Although the INSPIRES analysis delivers robust evidence across a large trial cohort, several scientific questions warrant further prospective study. First, researchers must determine whether serially monitoring oxidised low-density lipoprotein concentrations across convalescence provides superior prognostic value over single baseline measurements. In addition, prospective interventional trials should establish whether therapies that specifically neutralize oxidative stress can reduce recurrent ischaemic strokes without magnifying bleeding hazards.

Furthermore, scientists must evaluate these biomarker correlations across diverse ethnic populations. Because the INSPIRES trial primarily recruited Han Chinese participants with high rates of intracranial stenosis, validating these findings in global cohorts remains essential. Similarly, comparative analyses across distinct stroke subtypes, including cardioembolic and small vessel disease, will clarify whether this oxidative vulnerability applies uniformly. Finally, combining oxidised low-density lipoprotein with other circulating inflammatory markers, such as high-sensitivity C-reactive protein, may yield superior predictive algorithms. In summary, untangling oxidative lipid pathways provides a promising frontier for modern neurovascular medicine, paving the way for targeted therapies that safeguard both vascular patency and endothelial integrity.

Frequently Asked Questions

What is oxidised low-density lipoprotein and why is it dangerous?

Oxidised low-density lipoprotein represents chemically altered cholesterol particles damaged by reactive oxygen species. These modified particles stimulate endothelial inflammation, accelerate macrophage foam cell formation, and destabilize arterial fibrous caps. Consequently, they elevate systemic vascular vulnerability, predisposing stroke patients to acute arterial re-occlusion and microvascular rupture.

How did oxLDL levels influence 90-day stroke recurrence in the INSPIRES trial?

In the INSPIRES trial analysis, patients in the highest tertile of baseline oxidised low-density lipoprotein faced a 39% higher risk of recurrent stroke within 90 days compared with the lowest tertile. Furthermore, these patients experienced a 36% higher risk of composite vascular events after adjusting for confounding factors.

Why did higher oxLDL levels correlate with increased bleeding risk?

Oxidised low-density lipoprotein disrupts brain endothelial tight junctions and degrades the vascular basement membrane through matrix metalloproteinase induction. When patients concurrently take intensive antiplatelet therapy, this underlying microvascular fragility increases susceptibility to vessel rupture. Consequently, patients in the highest tertile demonstrated a 3.6-fold higher rate of moderate-to-severe haemorrhages.

Disclaimer: This content is for informational and educational purposes only. It does not constitute formal medical advice, diagnosis, or treatment recommendations. Clinical decisions should always be made by qualified healthcare professionals based on individual patient assessments and comprehensive diagnostic evaluations. Therapeutic protocols and pharmaceutical interventions must strictly adhere to officially approved indications, institutional guidelines, and regulatory frameworks. Dosage regimens, contraindications, and potential drug interactions require independent verification prior to administration. The authors and publishers accept no liability for any adverse clinical outcomes or operational consequences resulting from the practical application of this information. Refer to the latest local and national guidelines for clinical practice.

References

1. Ding Y et al. Oxidised low-density lipoprotein and adverse outcome in patients with acute mild ischaemic stroke or high-risk TIA: a secondary analysis of the INSPIRES randomised clinical trial. Stroke Vasc Neurol. 2025 Oct 27. doi: 10.1136/svn-2024-003664. PMID: 40010751.
2. Wang A, Xu J, Chen G, et al. Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology. 2018;91(10):e947-e955.
3. Gao Y, Chen W, Pan Y, et al. Dual antiplatelet therapy initiated within 72 hours of mild ischemic stroke or high-risk TIA (INSPIRES). N Engl J Med. 2023;389(26):2413-2424.
4. Wang A, Yang Y, Su Z, et al. Association of oxidized low-density lipoprotein with prognosis of stroke and stroke subtypes. Stroke. 2017;48(1):91-97.